Valneva COVID-19 vaccine
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | VLA2001,[1] VLA2101, COVID-19 Vaccine (inactivated, adjuvanted) Valneva[2] |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
|
| COVID-19 portal |
Valneva COVID-19 vaccine (VLA2001) is a COVID-19 vaccine developed by European specialty vaccine company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.[7][8][9]
In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do so. It was authorized for medical use in the European Union in June 2022.[3] It was authorized for medical use in the European Union in June 2022.[2]
- ^ "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Archived from the original on 13 January 2021. Retrieved 11 January 2021.
- ^ a b c "COVID-19 Vaccine (inactivated, adjuvanted) Valneva EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 28 June 2022. Retrieved 28 June 2022.
- ^ a b "Regulatory approval of COVID-19 Vaccine Valneva". Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original on 14 April 2022. Retrieved 14 April 2022.
- ^ Cite error: The named reference
MHRA20220414was invoked but never defined (see the help page). - ^ "COVID-19 Vaccine (inactivated, adjuvanted) Valneva Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF). Archived (PDF) from the original on 9 October 2024. Retrieved 24 September 2024.
- ^ "Dynavax Technologies Corp". Reuters. Archived from the original on 4 June 2022. Retrieved 4 June 2022.
- ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- ^ "Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine" (Press release). Valneva. Archived from the original on 7 April 2021. Retrieved 27 April 2021.